AR125046A1 - Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2 - Google Patents

Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2

Info

Publication number
AR125046A1
AR125046A1 ARP220100652A ARP220100652A AR125046A1 AR 125046 A1 AR125046 A1 AR 125046A1 AR P220100652 A ARP220100652 A AR P220100652A AR P220100652 A ARP220100652 A AR P220100652A AR 125046 A1 AR125046 A1 AR 125046A1
Authority
AR
Argentina
Prior art keywords
bcl
inhibitors
nitrophenyl
acetamide
sulfonyl
Prior art date
Application number
ARP220100652A
Other languages
English (en)
Inventor
Ruben Abagyan
Andrew Orry
Polo Chun Lam
- Savchuk Nikolay Hung
Original Assignee
Eil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eil Therapeutics Inc filed Critical Eil Therapeutics Inc
Publication of AR125046A1 publication Critical patent/AR125046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se dirige generalmente a inhibidores de proteínas BCL-2 útiles en el tratamiento de enfermedades y trastornos modulados por dicha enzima y que tienen la fórmula (1), y sales, isómeros, solvatos, profármacos o tautómeros farmacéuticamente aceptables del mismo, como se definen en las reivindicaciones, en donde: X se selecciona de N y CH; L se selecciona de enlace, alquilenilo C₁-C₆, alquenilenilo C₂-C₆, alquinilenilo C₂-C₆, -C(O)-, -C(O)O-, -C(O)NRL-, -NRL- y -O-; y RL se selecciona de H y alquilo C₁-C₃.
ARP220100652A 2021-03-19 2022-03-18 Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2 AR125046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163163326P 2021-03-19 2021-03-19

Publications (1)

Publication Number Publication Date
AR125046A1 true AR125046A1 (es) 2023-05-31

Family

ID=83321213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100652A AR125046A1 (es) 2021-03-19 2022-03-18 Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2

Country Status (11)

Country Link
US (1) US11834450B2 (es)
EP (1) EP4308092A1 (es)
JP (1) JP2024510434A (es)
KR (1) KR20230159524A (es)
CN (1) CN117642157A (es)
AR (1) AR125046A1 (es)
AU (1) AU2022240765A1 (es)
BR (1) BR112023017371A2 (es)
CA (1) CA3211639A1 (es)
MX (1) MX2023011000A (es)
WO (1) WO2022198069A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270660A (zh) * 2023-03-30 2023-06-23 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102001418B1 (ko) * 2009-05-26 2019-07-19 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
SG184094A1 (en) 2010-03-25 2012-10-30 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US10195213B2 (en) * 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
BR112020022092A2 (pt) * 2018-04-29 2021-02-02 Beigene, Ltd. compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica

Also Published As

Publication number Publication date
EP4308092A1 (en) 2024-01-24
CA3211639A1 (en) 2022-09-22
BR112023017371A2 (pt) 2023-10-03
US11834450B2 (en) 2023-12-05
JP2024510434A (ja) 2024-03-07
AU2022240765A1 (en) 2023-09-07
KR20230159524A (ko) 2023-11-21
WO2022198069A1 (en) 2022-09-22
CN117642157A (zh) 2024-03-01
US20220306625A1 (en) 2022-09-29
MX2023011000A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
PE20210004A1 (es) Inhibidores de mcl-1
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
DOP2021000038A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
CO6190525A2 (es) Fosfoindoles enantiomericamente puros como inhibidores de vih
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR066972A1 (es) Derivados azapeptidicos
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
AR087757A1 (es) Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas
CL2023003275A1 (es) Inhibidores alostéricos de la cromenona de la fosfoinositida 3-quinasa (pi3k) para el tratamiento de enfermedades.
HN2009001160A (es) Inhibidores de transcriptasa inversa no nucleosidicos
AR125046A1 (es) Compuestos que tienen ((3-nitrofenil)sulfonil)acetamida como inhibidores de bcl-2
CU20160183A7 (es) Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
CO2021004679A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
PE20210175A1 (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat)
CO6531478A2 (es) Derivados de etinilo
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
CO2022003829A2 (es) Moduladores de receptor alfa relacionado con estrógenos (errα)
CO2021017619A2 (es) Moduladores del receptor alfa relacionado con estrógeno (errα)
DE60313339D1 (de) Protein tyrosin kinase inhibitoren
AR061598A1 (es) Nitroderivados heterociclicos como antagonistas de receptor de endotelina
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados

Legal Events

Date Code Title Description
FB Suspension of granting procedure